Journal of Business Ethics

, Volume 122, Issue 3, pp 501–510 | Cite as

Moral Psychology and the Intuition that Pharmaceutical Companies Have a ‘Special’ Obligation to Society



Many people believe that the research-based pharmaceutical industry has a ‘special’ moral obligation to provide lifesaving medications to the needy, either free-of-charge or at a reduced rate relative to the cost of manufacture. In this essay, I argue that we can explain the ubiquitous notion of a special moral obligation as an expression of emotionally charged intuitions involving sacred or protected values and an aversive response to betrayal in an asymmetric trust relationship. I then review the most common arguments used to justify the claim that the pharmaceutical industry has a special moral obligation and show why these justifications fail. Taken together, these conclusions call into question the conventional ideologies that have traditionally animated the debate on whether the pharmaceutical industry has special duties of beneficence and distributive justice with respect to the impoverished in dire need of their products.


Access to lifesaving medicines Betrayal aversion Moral intuition Moral psychology Pharmaceutical industry Special moral obligation Taboo trade-off theory 


  1. Adams, M. O., & Osho, G. S. (2006). Drug company profits in the United States: are they excessive? Evidence from public administration perspectives. Journal of Business & Economics Research, 4(2), 85–90.Google Scholar
  2. Almashat, S., Preston, C., Waterman, T., & Wolfe, S. (2010). Rapidly increasing criminal and civil monetary penalties against the pharmaceutical industry: 1991 to 2010.
  3. Angell, M. (2004). The truth about drug companies. New York: Random House.Google Scholar
  4. Angell, M. (2008). Industry-sponsored clinical research: A broken system. Journal of the American Medical Association, 300(9), 1069–1071.CrossRefGoogle Scholar
  5. Armstrong v. United States, 364 U.S. 40. (1960). Supreme Court of the United States.
  6. Arrow, K. (1963). Uncertainty and the welfare economics of medical care. The American Economic Review, 53(5), 941–973.Google Scholar
  7. Bale, H. E. (1998). The conflicts between parallel trade and product access and innovation: the case of pharmaceuticals. Journal of International Economic Law, 1, 637–653.CrossRefGoogle Scholar
  8. Banerjee, A. (2006). Who has responsibility for access to essential medical drugs in the developing world? Ethics and Economics, 4(2), 1–23.Google Scholar
  9. Baron, J. (1998). Judgment misguided: Intuition and error in public decision making. New York: Oxford University Press.Google Scholar
  10. Baron, J., & Spranca, M. (1997). Protected values. Organizational Behavior and Human Decision Processes, 70(1), 1–16.Google Scholar
  11. Berenson, A. (2006, February 15). A cancer drug shows promise, at a price that many can’t pay. The New York Times.
  12. Bombardier, C., Laine, L., Reicin, A., Shaprio, D., Burgos-Vargas, R., Davis, B., et al. (2000). Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. The New England Journal of Medicine, 343(21), 1520–1528.CrossRefGoogle Scholar
  13. Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., et al. (2005). Cardiovascular effects associated with rofecoxib in a colorectal adenoma chemoprevention trial. The New England Journal of Medicine, 352(11), 1092–1102.CrossRefGoogle Scholar
  14. Brody, H. (2007). Hooked: Ethics, the medical profession, and the pharmaceutical industry. Lanham: Roman & Littlefield.Google Scholar
  15. Burke, E. (1790/1987). Reflections on the revolution in France (J. G. A. Pocock, Trans.). Indianapolis: Hackett.Google Scholar
  16. Carroll, A. B. (1999). Corporate social responsibility: Evolution of a definitional construct. Business & Society, 38(3), 268–295.CrossRefGoogle Scholar
  17. Chang, P. L. (2006). Who’s in the business of saving lives? Journal of Medicine and Philosophy, 31, 465–482.CrossRefGoogle Scholar
  18. Chitemerere, C. (2011). Pharmaceutical sector profile: Zimbabwe (D. Hubbard, Ed.). Vienna: United Nations Industrial Development Organization (UNIDO).
  19. Choo, C. W. (2008). Organizational disasters: Why they happen and how they may be prevented. Management Decision, 46(1), 323–345.CrossRefGoogle Scholar
  20. Clark, J. (2003). A hot flush for big pharma. British Medical Journal, 327(7411), 400.CrossRefGoogle Scholar
  21. Cockburn, I., & Henderson, R. (1996). Public–private interaction in pharmaceutical research. Proceedings of the National Academy of Sciences of the United States of America, 93, 12725–12730.CrossRefGoogle Scholar
  22. Cutler, D. M., Rosen, A. B., & Vijan, S. (2006). The value of medical spending in the United States, 1960–2000. New England Journal of Medicine, 355, 920–927.CrossRefGoogle Scholar
  23. De George, R. T. (2005). Intellectual property and pharmaceutical drugs: An ethical analysis. Business Ethics Quarterly, 15(4), 549–575.CrossRefGoogle Scholar
  24. Dorfler, V., & Ackermann, F. (2012). Understanding intuition: The case for two forms of intuition. Management Learning, 43(5), 545–564.CrossRefGoogle Scholar
  25. Durkheim, E. (1912/1995). The elementary forms of religious experience (K. E. Fields, Trans.). New York: The Free Press.Google Scholar
  26. The Economist. (2012, November 6). The drug industry doesn’t work. (Reprinted by permission, ©The Economist Newspaper Limited, London).
  27. Experts in Chronic Myeloid Leukemia. (2013). The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood, 121(22), 4439–4442.CrossRefGoogle Scholar
  28. Fan, S., & Rao, N. (2003). Public spending in developing countries: Trends, determination, and impact. Environment and Production Technology Division Discussion Paper No. 99. Washington, DC.Google Scholar
  29. Fiske, A. P. (1992). The four elementary forms of sociality: Framework for a unified theory of social relations. Psychological Review, 99(4), 689–723.CrossRefGoogle Scholar
  30. Fiske, A. P., & Tetlock, P. E. (1997). Taboo trade-offs: Reactions to transactions that transgress the spheres of justice. Political Psychology, 18(2), 225–297.CrossRefGoogle Scholar
  31. Fortune Magazine. (2011). 2011 Fortune 500.
  32. Greenwald, D. E. (1973). Durkheim on society, thought and ritual. Sociological Analysis, 34(3), 157–168.CrossRefGoogle Scholar
  33. Greve, J. (2008). Healthcare in developing countries and the role of business: A global governance framework to enhance the accountability of pharmaceutical companies. Corporate Governance, 8(4), 490–505.CrossRefGoogle Scholar
  34. Haidt, J. (2001). The emotional dog and its rational tail: A social intuitionist approach to moral judgement. Psychological Review, 108(4), 814–834.CrossRefGoogle Scholar
  35. Hardwig, J. (1985). Epistemic dependence. The Journal of Philosophy, 82(7), 335–349.CrossRefGoogle Scholar
  36. Harris, G. (2004). Drug companies seek to mend their image. The New York Times.
  37. Hasan, S., & Wanyanga, W. (2010). Pharmaceutical sector profile: Kenya (D. Hubbard, Ed.). Vienna: United Nations Industrial Development Organization (UNIDO).
  38. Herper, M. (2012, February 10). The truly staggering cost of inventing new drugs. Forbes.
  39. Hilts, P. J. (2003). Protecting America’s health. New York: Alfred A. Knopf.Google Scholar
  40. Hsieh, N. (2008). Incommensurable values. In E. N. Zalta (Ed.), The Stanford encyclopedia of philosophy.
  41. Hume, D. (1739/1985). A treatise of human nature. New York: Penguin.Google Scholar
  42. Jeske, D. (2008). Special obligations. In E. N. Zalta (Ed.), The Stanford encyclopedia of philosophy.
  43. Kaiser. (2005). Views on prescription drugs and the pharmaceutical industry. Kaiser Family Foundation Health Poll Report Survey.
  44. Kanavos, P., Costa-i-Font, J., Merkur, S., & Gemmill, M. (2004). The economic impact of pharmaceutical parallel trade in European Union member states: A stakeholder analysis. LSE Health and Social Care Special Research Paper.
  45. Karha, J., & Topol, E. J. (2004). The sad story of Vioxx, and what we should learn from it. Cleveland Clinic Journal of Medicine, 71(12), 933–939.CrossRefGoogle Scholar
  46. Koehler, J. J., & Gershoff, A. D. (2003). Betrayal aversion: When agents of protection become agents of harm. Organizational Behavior and Human Decision Processes, 90, 244–261.CrossRefGoogle Scholar
  47. Koroneos, G. (2009). Fixing Pfizers rep: An interview with Kathryn Metcalfe.
  48. Koski, E. G. (2005). Renegotiating the grand bargain. In M. A. Santoro & T. M. Gorrie (Eds.), Ethics and the pharmaceutical industry (pp. 393–403). New York: Cambridge University Press.CrossRefGoogle Scholar
  49. Lehman, B. (2003). The pharmaceutical industry and the patent system.
  50. Leisinger, K. M. (2005). The corporate social responsibility of the pharmaceutical industry: Idealism without illusions and realism without resignation. Business Ethics Quarterly, 15(4), 577–594.CrossRefGoogle Scholar
  51. Lewis, N. A., & Pear, R. (1994, March 07). U.S. drug industry fights reputation for price gouging. The New York Times.
  52. Light, D. W., & Warburton, R. (2012). The costly myths of pharmaceutical R&D.
  53. Maitland, I. (2002). Priceless goods: How should life-saving drugs be priced? Business Ethics Quarterly, 12(4), 451–480.CrossRefGoogle Scholar
  54. Maynard, A., & Bloor, K. (2003). Trust and performance management in the medical marketplace. Journal of the Royal Society of Medicine, 96, 532–539.CrossRefGoogle Scholar
  55. McGraw, A. P., Schwartz, J. A., & Tetlock, P. E. (2011). From the commercial to the communal: Reframing taboo trade-offs in religious and pharmaceutical marketing. Journal of Consumer Research, 39, 157–173.CrossRefGoogle Scholar
  56. Merck. (2004). Merck announces voluntary worldwide withdrawal of VIOXX. News Release, White House Station, NJ.Google Scholar
  57. Mill, J. S. (1861/2007). Utilitarianism. Mineola: Dover.Google Scholar
  58. Morel, C. M. (2003). Neglected diseases: Under-funded research and inadequate health interventions. European Molecular Biology Organization Reports, 4, S35–S38.Google Scholar
  59. Moynihan, R., Heath, I., & Henry, D. (2002). Selling sickness: The pharmaceutical industry and disease-mongering. British Medical Journal, 324, 886–891.CrossRefGoogle Scholar
  60. Nayyar, G. M. L., Breman, J. G., Newton, P. N., & Herrington, J. (2012). Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. The Lancet Infectious Diseases, 12(6), 488–496.CrossRefGoogle Scholar
  61. Pillay, N. (2008). Right to health and the Universal Declaration of Human Rights. The Lancet, 372(9655), 2005–2006.CrossRefGoogle Scholar
  62. Porter, M. E., & Kramer, M. R. (2006, December). Strategy & society: The link between competitive advantage and corporate social responsibility. Harvard Business Review, 84, 78–92.Google Scholar
  63. PricewaterhouseCoopers. (2006). Recapturing the vision—Restoring trust in the pharmaceutical industry by translating expectations into actions.
  64. Pyke, S., Julious, S. A., Day, S., O’Kelly, M., Todd, S., Matcham, J., et al. (2011). The potential for bias in reporting of industry-sponsored clinical trials. Pharmaceutical Statistics, 10(1), 74–79.CrossRefGoogle Scholar
  65. Raz, J. (1986). The morality of freedom. New York: Oxford University Press.Google Scholar
  66. Reisel, W. D., & Sama, L. M. (2003). The distribution of life-saving pharmaceuticals: Viewing the conflict between social efficiency and economic efficiency through a social contract lens. Business and Society Review, 108(3), 365–387.CrossRefGoogle Scholar
  67. Resnik, D. B. (2001). Developing drugs for the developing world: An economic, legal, moral, and political dilemma. Deveoping World Bioethics, 1(1), 11–32.CrossRefGoogle Scholar
  68. Robinson, P. H., & Kurzban, R. (2007). Concordance and conflict in intuitions of justice. Minnesota Law Review, 91, 1829–1907.Google Scholar
  69. Robinson, P. H., Kurzban, R., & Jones, O. D. (2007). The origins of shared intuitions of justice. Vanderbilt Law Review, 60(6), 1633–1688.Google Scholar
  70. Rugumambaju, S., & Kutyabami, P. (2010). Pharmaceutical sector profile: Uganda (D. Hubbard, Ed.). Vienna: United Nations Industrial Development Organization (UNIDO).
  71. Sampat, B. N., & Lichtenberg, F. R. (2011). What are the respective roles of the public and private sectors in pharmaceutical innovation? Health Affairs, 30(2), 332–339.CrossRefGoogle Scholar
  72. Santoro, M. A. (2005). Introduction: Creating a sustainable path for the twenty-first century pharmaceutical industry. In M. A. Santoro & T. M. Gorrie (Eds.), Ethics and the pharmaceutical industry (pp. 1–5). New York: Cambridge University Press.CrossRefGoogle Scholar
  73. Sauer, H. (2011). Social intuitionism and the psychology of moral reasoning. Philosophy Compass, 6(10), 708–721.CrossRefGoogle Scholar
  74. Shirley, D. A., & Langan-Fox, J. (1996). Intuition: A review of the literature. Psychological Reports, 79, 563–584.CrossRefGoogle Scholar
  75. Singer, P. (1972). Famine, affluence, and morality. Philosophy & Public Affairs, 1(3), 229–243.Google Scholar
  76. Spinello, R. A. (1992). Ethics, pricing and the pharmaceutical industry. Journal of Business Ethics, 11, 617–626.CrossRefGoogle Scholar
  77. Taurel, S. (2005). The campaign against innovation. In M. A. Santoro & T. M. Gorrie (Eds.), Ethics and the pharmaceutical industry. New York: Cambridge University Press.Google Scholar
  78. Tetlock, P. E. (2002). Social functionalist frameworks for judgment and choice: Intuitive politicians, theologians, and prosecutors. Psychological Review, 109(3), 451–471.CrossRefGoogle Scholar
  79. Tetlock, P. E., Kristel, O. V., Elson, S. B., Green, M. C., & Lerner, J. S. (2000). The psychology of the unthinkable: Taboo trade-offs, forbidden base rates, and heretical counterfactuals. Journal of Personality and Social Psychology, 78(5), 853–870.CrossRefGoogle Scholar
  80. The New York Times. (1994). Taxpayers may be paying twice for some drugs.
  81. United Nations. (2008). UN General Assembly: the right to health/note by the Secretary-General, 11 August 2008, A/63/263.Google Scholar
  82. Wambebe, C., & Ochekpe, N. (2011). Pharmaceutical sector profile: Nigeria. Vienna: United Nations Industrial Development Organization (UNIDO).
  83. Weber, L. J. (2001). Business ethics in healthcare: Beyond compliance. Bloomington: Indiana University Press.Google Scholar
  84. Wolf, S. (2009). Moral obligations and social commands. In S. Newlands & L. M. Jorgensen (Eds.), Metaphysics and the good: Themes from the philosophy of Robert Merrihew Adams (pp. 343–367). New York: Oxford University Press.CrossRefGoogle Scholar
  85. Zucker, L. G. (1987). Institutional theories of organization. Annual Review of Sociology, 13, 443–464.Google Scholar
  86. Zycher, B., & DiMasi, J. A. (2008). The truth about drug innovation: Thirty-five summary case histories on private sector contributions to pharmaceutical science. Medical Progress Report (Vol. 6). Center for Medical Progress at the Manhattan Institute.
  87. Zyzik, R. (2011). Normativity and moral psychology: Social intuitions model and the world without normative moral rules? In J. Stelmach & B. B Brożek (Eds.), Studies in the philosophy of law: The normativity of law (pp. 213–226). Kraków: Copernicus Center Press.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  1. 1.Department of PhilosophySuffolk UniversityBostonUSA

Personalised recommendations